Targeting histone deacetylase (HDAC-1 and HDAC-2) as mechanisms to induce fetal hemoglobin in sickle cell disease

• Grant number: 15/19531-1
• Support Opportunities: Regular Research Grants
• Start date: May 01, 2016
• End date: April 30, 2018
• Field of knowledge: Health Sciences - Pharmacy - Medicines Analysis and Control
• Principal Investigator: Jean Leandro dos Santos
• Grantee: Jean Leandro dos Santos
• Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
• Associated researchers: Carolina Lanaro ; Chung Man Chin ; Fernando Ferreira Costa

Abstract

Sickle cell disease (SCD) is one of the most prevalent chronic hereditary hemoglobinopathies worldwide. Currently, the only drug available for its treatment is hydroxyurea, responsible among other actions, to increase the levels of fetal hemoglobin (HbF). Gamma-globin gene regulation is complex and involves various proteins and enzymes, such as histone deacetylase (HDAC). HADC inhibitors, like the butyrate has shown effect to induce HbF levels both in vitro and in vivo. Class I HDAC inhibition, specifically HDAC-1 and HDAC-2, proved to be a promising strategy to promote increased gene expression of gamma-globin and production of HbF without causing changes in the cell cycle and proliferation.In this proposal, in continuity with our research aiming to identify new drugs to treat SCD symptoms, we describe herein the synthesis and pharmacological evaluation of new compounds designed as HDAC-1 and HDAC-2 inhibitors obtained by molecular hybridization approach. (AU)

Scientific publications

(12)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

PAVAN, ALINE RENATA; DOS SANTOS, JEAN LEANDRO. Advances in Sickle Cell Disease Treatments. Current Medicinal Chemistry, v. 28, n. 10, p. 2008-2032, 2021. (18/19523-7, 15/19531-1)

PAVAN, ALINE RENATA; BERNARDES DA SILVA, GABRIEL DALIO; JORNADA, DANIELA HARTMANN; CHIBA, DIEGO EIDY; DOS SANTOS FERNANDES, GUILHERME FELIPE; CHIN, CHUNG MAN; DOS SANTOS, JEAN LEANDRO. Unraveling the Anticancer Effect of Curcumin and Resveratrol. NUTRIENTS, v. 8, n. 11, NOV 2016. (15/19531-1, 16/08470-4, 14/14980-0, 15/21252-3, 14/24811-0, 14/02240-1)

DUTRA, LUIZ ANTONIO; HEIDENREICH, DAVID; BERNARDES DA SILVA, GABRIEL DALIO; CHIN, CHUNG MAN; KNAPP, STEFAN; DOS SANTOS, JEAN LEANDRO. Dietary Compound Resveratrol Is a Pan-BET Bromodomain Inhibitor. NUTRIENTS, v. 9, n. 11, NOV 2017. (15/19531-1, 16/08880-8, 14/03945-9)

DE SOUZA, P. C.; FERNANDES, G. F. S.; MARINO, L. B.; RIBEIRO, C. M.; DA SILVA, P. B.; CHORILLI, M.; SILVA, C. S. P.; RESENDE, F. A.; SOLCIA, M. C.; DE GRANDIS, R. A.; et al. Furoxan derivatives demonstrated in vivo efficacy by reducing Mycobacterium tuberculosis to undetectable levels in a mouse model of infection. BIOMEDICINE & PHARMACOTHERAPY, v. 130, OCT 2020. (18/11079-0, 18/00163-0, 14/03920-6, 17/12419-7, 16/09502-7, 14/02240-1, 13/14957-5, 16/02860-5, 14/24811-0, 16/24633-0, 18/17739-2, 15/19531-1, 16/22429-7, 14/11586-9)

URIAS, BEATRIZ SILVA; PAVAN, ALINE RENATA; ALBUQUERQUE, GABRIELA RIBEIRO; PROKOPCZYK, IGOR MUCCILO; FERREIRA ALVES, TANIA MARA; FERREIRA DE MELO, THAIS REGINA; RODRIGUES SARTORI, GERALDO; MARTINS DA SILVA, JOAO HERMINIO; CHIN, CHUNG MAN; DOS SANTOS, JEAN LEANDRO. Optimization of Resveratrol Used as a Scaffold to Design Histone Deacetylase (HDAC-1 and HDAC-2) Inhibitors. PHARMACEUTICALS, v. 15, n. 10, p. 18-pg., 2022-10-01. (18/11079-0, 17/07789-0, 18/19523-7, 15/19531-1, 15/21252-3, 19/09456-3)

DUTRA, LUIZ ANTONIO; GUANAES, JESSICA FRADE O.; JOHMANN, NADINE; LOPES PIRES, MARIA ELISA; CHIN, CHUNG MAN; MARCONDES, SISI; DOS SANTOS, JEAN LEANDRO. Synthesis, antiplatelet and antithrombotic activities of resveratrol derivatives with NO-donor properties. Bioorganic & Medicinal Chemistry Letters, v. 27, n. 11, p. 2450-2453, JUN 1 2017. (15/19531-1, 11/15520-4, 15/21271-8, 14/03945-9)

DOS SANTOS FERNANDES, GUILHERME FELIPE; PAVAN, ALINE RENATA; DOS SANTOS, JEAN LEANDRO. Heterocyclic N-oxides - A Promising Class of Agents against Tuberculosis, Malaria and Neglected Tropical Diseases. CURRENT PHARMACEUTICAL DESIGN, v. 24, n. 12, p. 1325-1340, 2018. (15/21252-3, 16/09502-7, 15/19531-1)

FERREIRA DE MELO, THAIS REGINA; DULMOVITS, BRIAN M.; DOS SANTOS FERNANDES, GUILHERME FELIPE; DE SOUZA, CRISTIANE M.; LANARO, CAROLINA; HE, MINGHZU; AL ABED, YOUSEF; CHUNG, MAN CHIN; BLANC, LIONEL; COSTA, FERNANDO FERREIRA; et al. Synthesis and pharmacological evaluation of pomalidomide derivatives useful for sickle cell disease treatment. BIOORGANIC CHEMISTRY, v. 114, SEP 2021. (16/09502-7, 15/19531-1, 13/04244-1, 10/12495-6, 14/00984-3, 14/06755-6)

DOS SANTOS FERNANDES, GUILHERME FELIPE; DE SOUZA, PAULA CAROLINA; MORENO-VIGURI, ELSA; SANTIVANEZ-VELIZ, MERY; PAUCAR, ROCIO; PEREZ-SILANES, SILVIA; CHEGAEV, KONSTANTIN; GUGLIELMO, STEFANO; LAZZARATO, LORETTA; FRUTTERO, ROBERTA; et al. Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity. Journal of Medicinal Chemistry, v. 60, n. 20, p. 8647-8660, OCT 26 2017. (15/19531-1, 13/14957-5, 14/24811-0, 14/11586-9, 14/03920-6, 16/09502-7, 16/02860-5, 14/02240-1)

CHELUCCI, RAFAEL C.; DE OLIVEIRA, ISABELA J.; BARBIERI, KARINA P.; LOPES-PIRES, MARIA E.; POLESI, MARISA C.; CHIBA, DIEGO E.; CARLOS, IRACILDA Z.; MARCONDES, SISI; DOS SANTOS, JEAN L.; CHUNG, MANCHIN. Antiplatelet activity and TNF- release inhibition of phthalimide derivatives useful to treat sickle cell anemia. MEDICINAL CHEMISTRY RESEARCH, v. 28, n. 8, p. 1264-1271, AUG 2019. (15/19531-1, 13/23461-3)

SANTOS FERNANDES, GUILHERME FELIPE; BERNARDES SILVA, GABRIEL DALIO; PAVAN, ALINE RENATA; CHIBA, DIEGO EIDY; CHIN, CHUNG MAN; DOS SANTOS, JEAN LEANDRO. Epigenetic Regulatory Mechanisms Induced by Resveratrol. NUTRIENTS, v. 9, n. 11, NOV 2017. (15/19531-1, 16/08470-4, 16/08880-8, 16/09502-7)

PAVAN, ALINE RENATA; LOPES, JULIANA ROMANO; DOS SANTOS, JEAN LEANDRO. The state of the art of fetal hemoglobin-inducing agents. EXPERT OPINION ON DRUG DISCOVERY, v. 17, n. 11, p. 15-pg., 2022-11-07. (18/19523-7, 21/10059-9, 20/13279-7, 15/19531-1, 10/12495-6, 12/50359-2, 15/21252-3)